Brokerages Expect Global Blood Therapeutics Inc (NASDAQ:GBT) Will Announce Earnings of -$1.19 Per Share

Wall Street analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings of ($1.19) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($1.13) and the lowest is ($1.30). Global Blood Therapeutics posted earnings of ($0.93) per share in the same quarter last year, which would suggest a negative year over year growth rate of 28%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 26th.

On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.27) to ($4.09). For the next fiscal year, analysts forecast that the company will report earnings of ($4.61) per share, with EPS estimates ranging from ($5.57) to ($4.02). Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the company earned ($0.83) EPS.

GBT has been the topic of a number of research reports. Janney Montgomery Scott raised their price objective on Global Blood Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Cowen set a $83.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 9th. Piper Jaffray Companies boosted their target price on Global Blood Therapeutics from $80.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Global Blood Therapeutics in a research note on Thursday, September 5th. Finally, Wedbush restated a “buy” rating and set a $143.00 price objective on shares of Global Blood Therapeutics in a research note on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $91.44.

In other Global Blood Therapeutics news, insider Joshua Lehrer-Graiwer sold 11,593 shares of Global Blood Therapeutics stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $67.19, for a total transaction of $778,933.67. Following the completion of the sale, the insider now directly owns 312 shares in the company, valued at approximately $20,963.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider De Dominicis Robert 490,012 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. In the last ninety days, insiders have sold 36,616 shares of company stock valued at $2,096,540. 4.30% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Quest Capital Management Inc. ADV purchased a new stake in shares of Global Blood Therapeutics during the 3rd quarter worth approximately $26,000. Steward Partners Investment Advisory LLC acquired a new stake in Global Blood Therapeutics in the second quarter valued at $27,000. Lindbrook Capital LLC boosted its position in shares of Global Blood Therapeutics by 133.3% during the 3rd quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock worth $34,000 after purchasing an additional 400 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Global Blood Therapeutics during the 2nd quarter worth $42,000. Finally, Truvestments Capital LLC grew its stake in shares of Global Blood Therapeutics by 48.0% during the 3rd quarter. Truvestments Capital LLC now owns 925 shares of the company’s stock worth $45,000 after purchasing an additional 300 shares during the period. 98.78% of the stock is currently owned by institutional investors and hedge funds.

Global Blood Therapeutics stock traded up $0.44 during mid-day trading on Wednesday, reaching $72.93. The company’s stock had a trading volume of 68,652 shares, compared to its average volume of 1,331,700. The firm’s fifty day moving average price is $53.03 and its two-hundred day moving average price is $53.44. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.95 and a current ratio of 14.95. Global Blood Therapeutics has a 12-month low of $34.92 and a 12-month high of $73.23. The company has a market capitalization of $4.01 billion, a P/E ratio of -21.39 and a beta of 1.70.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: How is a price target determined?

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.